Related Experiment Video

Updated: Aug 26, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Rational peptide-based tumour vaccine development and T cell monitoring

Carmen Scheibenbogen1, Anne Letsch, Alexander Schmittel

  • 1Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, Charite, Campus Benjamin Franklin, Free and Humbold University, Berlin, Germany.

Seminars in Cancer Biology
|March 6, 2004
PubMed

Insights

Antigen-specific cancer vaccination shows promise, with early trials indicating tumor regressions in some patients. Advanced T-cell assays are crucial for developing more effective cancer vaccines and correlating T-cell responses with clinical outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Antigen-specific vaccination is an emerging cancer treatment.
  • Early trials with tumor peptides showed limited tumor regressions in metastatic cancer patients.
  • Current research focuses on enhancing vaccine potency and targeting early-stage metastatic disease.

Purpose of the Study:

  • To explore the potential of antigen-specific vaccination in cancer treatment.
  • To highlight the role of novel T-cell assays in vaccine development.
  • To investigate the correlation between T-cell induction and clinical efficacy in cancer vaccination.

Main Methods:

  • Utilizing tumor peptides for vaccination in clinical trials.
  • Employing sensitive T-cell assays for quantitation and characterization of specific T cells.
  • Systematic clinical development of vaccine protocols.

Main Results:

  • Tumor regressions observed in a subset of patients with metastatic disease.
  • Advancements in T-cell assays enable precise measurement of immune responses.
  • Evidence suggests a link between specific T-cell induction and treatment effectiveness.

Conclusions:

  • Antigen-specific vaccination is a promising strategy for cancer therapy.
  • Sensitive T-cell assays are vital for the advancement of cancer vaccines.
  • Clinical efficacy of cancer vaccines is associated with the induction of specific T cells.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...